neurodegenerative diseases
Media
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Mental Health Portfolio
In a significant move that reshapes the landscape of mental health therapeutics, Johnson & Johnson (NYSE: JNJ) announced today its acquisition of Intra-Cellular...
